Thors H, Sigurdsson H, Oddsson E, Thjodleifsson B
Dept. of Medicine, Landspítalinn, Reykjavik, Iceland.
Scand J Gastroenterol. 1994 Nov;29(11):988-94. doi: 10.3109/00365529409094875.
The consumption of peptic ulcer drugs in Iceland is 20 DDD/1000/day, which is two to three times higher than in other Scandinavian countries. This study was done to register the pattern of use and possibly to find reasons for the high consumption.
Prescriptions for peptic ulcer drugs (ACT class AO2B) were surveyed in Iceland during 1 month in 1991. All pharmacies in Iceland participated in the study, and information was obtained on about 90% of peptic ulcer drugs used outside hospitals. The pharmacists registered all prescriptions of peptic ulcer drugs with regard to the age and sex of the patient, speciality of the prescribing physician, and name, dose, and quantity of the drug.
A total of 2021 prescriptions were registered, accounting for 15.4 DDD/1000/day. The prevalence of peptic ulcer drug use was 1.52%, but female use was 52.5%. The maximal use, 2.91% was in the age group 70-79 years. H2 blockers accounted for 79%, omeprazole for 17%, and other drugs for 4%. General practitioners prescribed 65% of the drugs, gastroenterologists 15%, and other specialists 14%. If the patient himself collected the drug, he was asked to fill out a questionnaire with regard to the reason for the prescription, previous prescriptions, and investigations. A total of 1131 (56%) of patient questionnaires were received. Only 1% of the patients did not know the reason for the prescription. The patients registered that 30% of the prescriptions were for peptic ulcer, 29% for heartburn, 21% for gastritis, 9% for dyspepsia, and 7% for prevention of side effects of other drugs. It was estimated from the data that about 40% of the prescriptions were for non-ulcer dyspepsia. Investigations were done in 67% of the patients, but 33% received the prescription only after an appointment with a physician.
The results of the survey suggest that the extensive use of peptic ulcer drugs in Iceland is mostly due to excessive use in non-ulcer dyspepsia.
冰岛消化性溃疡药物的消耗量为每日每1000人20限定日剂量（DDD），这比其他斯堪的纳维亚国家高出两到三倍。开展这项研究是为了记录用药模式，并可能找出高消耗量的原因。
1991年在冰岛对1个月内的消化性溃疡药物（ACT分类AO2B）处方进行了调查。冰岛所有药房都参与了该研究，获得了约90%在医院外使用的消化性溃疡药物的信息。药剂师记录了所有消化性溃疡药物处方中患者的年龄和性别、开处方医生的专业以及药物的名称、剂量和数量。
共记录了2021张处方，相当于每日每1000人15.4 DDD。消化性溃疡药物的使用率为1.52%，但女性使用率为52.5%。使用率最高的是70 - 79岁年龄组，为2.91%。H2受体阻滞剂占79%，奥美拉唑占17%，其他药物占4%。全科医生开出了65%的药物，胃肠病学家开出15%，其他专科医生开出14%。如果患者本人取药，会被要求填写一份关于处方原因、既往处方和检查情况的问卷。共收到1131份（56%）患者问卷。只有1%的患者不知道处方原因。患者记录显示，30%的处方用于消化性溃疡，29%用于胃灼热，21%用于胃炎，9%用于消化不良，7%用于预防其他药物的副作用。根据数据估计，约40%的处方用于非溃疡性消化不良。67%的患者进行了检查，但33%的患者是在预约医生后才拿到处方。
调查结果表明，冰岛消化性溃疡药物的广泛使用主要是由于非溃疡性消化不良的过度用药。
